Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-24-046468

← back to feed
Filed
Nov 18, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Nov 18, 2024 70.77M sh
Shares Diluted Q1 2025 · Sep 30, 2024 70.47M sh
Shares Diluted Q1 2025 · Sep 30, 2023 64.57M sh
Operating Cash Flow Q1 2025 · Sep 30, 2024 −$9.23K
Operating Cash Flow Q1 2025 · Sep 30, 2023 −$17.08K
Cash And Equivalents Q1 2025 · Sep 30, 2024 $4.95K
Cash And Equivalents Q1 2025 · Jun 30, 2024 $4.18K
Stockholders Equity Q1 2025 · Sep 30, 2024 −$391.75K
Stockholders Equity Q1 2025 · Jun 30, 2024 −$361.25K
Stockholders Equity Q1 2025 · Sep 30, 2023 −$290.8K
Stockholders Equity Q1 2025 · Jun 30, 2023 −$252.01K
Current Liabilities Q1 2025 · Sep 30, 2024 $396.7K
Current Liabilities Q1 2025 · Jun 30, 2024 $365.43K
Total Liabilities Q1 2025 · Sep 30, 2024 $396.7K
Total Liabilities Q1 2025 · Jun 30, 2024 $365.43K
Current Assets Q1 2025 · Sep 30, 2024 $4.95K
Current Assets Q1 2025 · Jun 30, 2024 $4.18K
Total Assets Q1 2025 · Sep 30, 2024 $4.95K
Total Assets Q1 2025 · Jun 30, 2024 $4.18K
Eps Diluted Q1 2025 · Sep 30, 2024 $0.00
Eps Diluted Q1 2025 · Sep 30, 2023 −$0.00
Eps Basic Q1 2025 · Sep 30, 2024 $0.00
Eps Basic Q1 2025 · Sep 30, 2023 −$0.00
Sga Expense Q1 2025 · Sep 30, 2024 $3.03K
Sga Expense Q1 2025 · Sep 30, 2023 $46.46K
Rd Expense Q1 2025 · Sep 30, 2024 $0
Rd Expense Q1 2025 · Sep 30, 2023 $0
Net Income Q1 2025 · Sep 30, 2024 −$32K
Net Income Q1 2025 · Sep 30, 2023 −$74.92K
Operating Income Q1 2025 · Sep 30, 2024 −$11.57M